Related Experiment Video
Updated: Jun 8, 2026
11:32
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Steroids in severe community-acquired pneumonia
Sachin Ananth1, Alexander G Mathioudakis2,3, Jan Hansel2,3
1London North West University Healthcare NHS Trust, London, UK.
Breathe (Sheffield, England)
|October 3, 2024
Summary
Hydrocortisone shows promise in treating severe community-acquired pneumonia (CAP), reducing mortality and the need for interventions. Further research is needed to confirm long-term benefits and optimal steroid dosing for CAP.
Area of Science:
- Critical Care Medicine
- Pulmonology
- Pharmacology
Background:
- Conflicting evidence exists on steroid use in severe community-acquired pneumonia (CAP).
- Previous trials were limited by small sample sizes.
- Two large trials, ESCAPe and CAPE COD, provide new insights.
Purpose of the Study:
- To compare the efficacy of different steroid regimens in severe CAP.
- To evaluate the impact of timing of steroid administration.
- To analyze outcomes based on patient characteristics.
Main Methods:
- ESCAPe trial: Methylprednisolone initiated 72-96 hours post-admission.
- CAPE COD trial: Hydrocortisone initiated within 24 hours of severe CAP development.
- Comparison of all-cause mortality, intubation, and shock rates.
Main Results:
- ESCAPe found no significant difference in mortality or secondary outcomes.
- CAPE COD demonstrated reduced 28-day mortality with hydrocortisone.
- Hydrocortisone also reduced the risk of intubation or vasopressor-dependent shock in CAPE COD.
Conclusions:
- Hydrocortisone initiation within 24 hours of severe CAP may improve outcomes.
- Differences in steroid type, timing, and patient populations (e.g., diabetes) influenced trial results.
- Further research is required for long-term outcomes and optimal steroid dosing strategies in severe CAP.
More Related Videos
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
The pathophysiology of pneumonia involves the following steps:
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...